India has often been called the 'pharmacy of the developing world' for providing high-quality and affordable generic and life-saving medicines. Having developed its own alternative model of conforming to the TRIPS Agreement, which is perceived as being in direct opposition to the US model of patent law, India has faced stiff opposition to its patent law reforms in the form of counter-provisions in the free trade Agreements entered into by the US and other Countries.